Current Status of Biologics in Perioperative Treatment for Resectable or Borderline Resectable Liver Metastases

Hannah Lu Chang, Amy Little Jones

Research output: Contribution to journalReview articlepeer-review

Abstract

Purpose of Review: This review provides an overview of the current role of biologics, anti-vascular endothelial growth factor (VEGF) inhibitors and anti-epidermal growth factor receptor (EGFR) inhibitors, in the perioperative treatment of colorectal liver metastases as well as a discussion of their future trends. Recent Findings: Over the past decade, a number of clinical trials have suggested that the use of biologics with cytotoxic agents may increase median overall survival in certain subsets of patients with colorectal liver metastases. The benefit of these agents is limited to borderline resectable and unresectable hepatic metastases and is not seen in upfront resectable disease. In the RAS wild-type population, the difference in efficacy of VEGF and EGFR inhibitors in combination with chemotherapy is minimal. These agents perform differently depending on primary tumor location; bevacizumab has greater efficacy in right-sided tumors, whereas cetuximab has greater efficacy in left-sided tumors. While biologics benefit patients in the neoadjuvant setting, studies have not shown similar results in the adjuvant setting. Summary: Given the variability of patient presentations as well as the risk of treatment-related toxicity, the addition of biologics requires careful consideration of patient’s medical fitness, surgical risk, and tumor profile.

Original languageEnglish (US)
Pages (from-to)10-22
Number of pages13
JournalCurrent Colorectal Cancer Reports
Volume17
Issue number1
DOIs
StatePublished - Feb 2021

Keywords

  • Bevacizumab
  • Cetuximab
  • Colorectal cancer
  • Liver metastases
  • Metastasectomy

ASJC Scopus subject areas

  • Hepatology
  • Oncology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Current Status of Biologics in Perioperative Treatment for Resectable or Borderline Resectable Liver Metastases'. Together they form a unique fingerprint.

Cite this